摘要
目的旨在讨论丙种球蛋白静脉滴注于新生儿败血症辅助治疗环节中的运用价值。方法本次研究选择2018年3月-2019年5月医院收治的患有败血症的120例患儿作为研究对象,按照随机分配的方式将患儿分为对照组与试验组,每组60例。其中,对照组采用常规抗感染以及保温等治疗方式,试验组则在此基础之上采用丙种球蛋白静脉滴注作为辅助治疗方式,对比两组患儿败血症的控制效果。结果试验组总有效率达到98.33%,高于对照组(70.00%),差异具有统计学意义(P<0.05)。试验组患儿体温降低时间、血培养转阴时间以及平均住院时间分别为(1.12±0.22)d、(1.14±0.25)d以及(3.25±0.23)d,高于对照组,组间数据差异有统计学意义(P<0.05)。结论丙种球蛋白静脉滴注于新生儿败血症辅助治疗工作中疗效显著,可加快血常规以及患儿体温的恢复速度,并优化患儿炎性因子,安全且切实可行。
Objective To discuss the value of intravenous gamma globulin infusion in adjuvant treatment of neonatal sepsis.Methods From March 2018 to May 2019,120 children with sepsis admitted to our hospital were selected as the research object.The children were randomly divided into control group and experimental group,60 cases in each group.Among them,the control group was treated with conventional anti-infection and heat preservation,while the experimental group was treated with intravenous gamma globulin drip as an adjuvant treatment,and the control effect of sepsis was compared between the two groups.Results The total effective rate of the experimental group was 98.33%,which was higher than that of the control group(70.00%).There was significant difference between the two groups(P<0.05).The time of hypothermia,negative blood culture and average hospitalization in the experimental group were(1.12±0.22)d,(1.14±0.25)D and(3.25±0.23)d,respectively,which were higher than those in the control group.There was a significant difference between the two groups(P<0.05).Conclusion Intravenous gamma globulin infusion is effective in the adjuvant treatment of neonatal sepsis.It can accelerate the recovery of blood routine and body temperature of children,and optimize the inflammatory factors of children.It is safe and feasible.
作者
潘莎
PAN Sha(Department of Neonatology,Xianning Central Hospital/The First Affiliated Hospital of Hubei University of Science and Technology,Xianning Hubei 437000,China)
出处
《中国继续医学教育》
2020年第27期158-160,共3页
China Continuing Medical Education
关键词
丙种球蛋白静脉滴注
败血症
新生儿
辅助治疗
抗感染
疗效
控制率
intravenous gamma globulin infusion
sepsis
neonates
adjuvant therapy
anti-infection
efficacy
control rate